Deutsche Bank Downgrades Novo Nordisk to Sell as Stock Plunges 70% from Peak
Nashnova编辑部
Deutsche Bank cut Novo Nordisk to sell with a DKK 265 target — a 9% trim — making it one of just four bearish voices on Wall Street. The stock has shed roughly 70% since its June 2024 peak, yet pipeline setbacks and growth doubts keep piling up.
Why is Deutsche Bank calling "sell" now?
Analyst Emmanuel Papadakis downgraded Novo from hold straight to sell, setting a target of DKK 265 — about 11% below the current price of DKK 299.
This means → he believes a 70% drawdown still hasn't found the floor.
Shares fell roughly 2% in early trading on the news — the market remains highly sensitive to outright sell ratings on this name.
Where does the rest of Wall Street stand?
Per FactSet, 62% of analysts still rate Novo a hold, 26% say buy, and only four — Deutsche Bank included — have an underperform or sell rating.
In plain terms = the vast majority are on the sidelines. Deutsche Bank is one of the very few willing to be explicitly bearish.
This reflects a market stuck in limbo: no catalyst to buy, but no courage to sell after a 70% drop either.
How many negatives are stacking up?
Pipeline failure: the late-stage trial for ziltivekimab — an anti-inflammatory drug candidate — missed its primary endpoint. Papadakis says the program is "effectively out."
Policy upside fizzles: U.S. Medicare added Wegovy coverage for cardiovascular patients, but the expected sales boost "looks quite limited."
Long-term growth in doubt: the market questions whether Novo can resume growth by 2027, and further out the company faces a sizable patent cliff — the risk that revenue drops sharply once key drug patents expire and generics flood in.
What is the next make-or-break moment?
The September 21 Capital Markets Day is the next validation window — Papadakis flags "information uncertainty" ahead of it.
This means → whether management can show fresh pipeline progress or a credible growth path on that day will directly determine if the valuation can stabilize.
In plain terms = the bad news is largely priced in, but the market still hasn't seen where the good news comes from — Capital Markets Day is Novo's last clear window to answer that question.
市场有风险，内容仅供研究参考，不构成投资建议。